11:25 ETStrategic Collaboration | Sanyou Bio and Baiyunshan Xihe Join Forces to Advance Innovative Radiopharmaceuticals and Radiodiagnosticsprnewswire·Jul 4 at 10:27 AM00874+6.00%600332+0.36%
China’s Guangzhou Pharma Expands Central Asia Footprint Through Series of PartnershipsYicai·Jun 9 at 08:03 AM600332+0.36%603235+0.17%
Chun Guang Intelligent (920810): Won the procurement project of Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd., with a bid amount of 2.397 million yuan同壁财经·Jun 2 at 12:35 AM00874+6.00%600332+0.36%
Baiyunshan Q1 Revenue Rises as Profit Margins Narrow and Cash Outflows EaseTip Ranks·Apr 27 at 06:10 AM600332+0.36%00874+6.00%
"Performance" Baiyunshan's annual net profit is 2.983 billion RMB, an increase of 5.2%, with a final dividend of 0.45 yuanAASTOCKS·Mar 22 at 03:53 AM589720+0.35%159859+1.32%
With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibitedWallstreetcn·Jan 27 at 04:41 AM512290+0.60%159929+0.68%
BAIYUNSHAN PH plans to develop an advanced manufacturing center in Hong KongAASTOCKS·Jan 8 at 07:08 PM600332+0.36%00874+6.00%
BAIYUNSHAN PH fully acquires ZMC distribution company for a consideration of 500 million RMBAASTOCKS·Dec 17, 2025 at 09:13 AM600216+8.00%600332+0.36%
Guangyao Group established an animal health technology company with a registered capital of 200 millionZhitong·Oct 30, 2025 at 01:07 AM600332+0.36%00874+6.00%
Understanding the Market | BAIYUNSHAN PH rose over 4% after earnings, with net profit attributable to shareholders for the first three quarters at 3.31 billion yuan; its Wanglaoji International can product has debuted in the Middle East marketZhitong·Oct 29, 2025 at 09:21 PM600332+0.36%00874+6.00%
BAIYUNSHAN PH released its performance for the first three quarters, with a net profit attributable to shareholders of RMB 3.31 billion, an increase of 4.78% year-on-yearZhitong·Oct 28, 2025 at 05:15 AM600332+0.36%00874+6.00%
BAIYUNSHAN PH: Third quarter net profit of 794 million yuan, a year-on-year increase of 30.28%Zhitong·Oct 28, 2025 at 04:37 AM600332+0.36%00874+6.00%
BAIYUNSHAN PH: Ke Gan Li Yan Oral Solution enters Phase III clinical trialsZhitong·Oct 17, 2025 at 03:59 AM600332+0.36%00874+6.00%
